Canaccord Genuity Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $30
Tango Therapeutics, Inc. +6.39%
Tango Therapeutics, Inc. TNGX | 26.64 | +6.39% |
Canaccord Genuity analyst John Newman initiates coverage on Tango Therapeutics (NASDAQ:
TNGX) with a Buy rating and announces Price Target of $30.
